Medicine & Health

IF selnoflast (IZD334; oral NLRP3 ATPase inhibitor, Phase 2 clinical candidate) is administered at a dose extrapolated from human Phase 2 pharmacokinetics (~100 mg/kg/day oral gavage, bridging from published murine MCC950 equivalence) to aged (20–22 month), male and female C57BL/6J mice carrying an established TET2-heterozygous CHIP clone generated by competitive bone marrow transplantation (50:50 TET2+/− : wild-type donor HSCs into lethally irradiated aged recipients, allowed 16 weeks engraftment prior to treatment), with a parallel PAI-1 neutralizing antibody co-arm (tiplaxtinin/PAI-039 or anti-PAI-1 monoclonal, i.p., 3×/week),

THEN the variant allele frequency (VAF) of the TET2-mutant clone — measured serially by droplet digital PCR (ddPCR) of peripheral blood and confirmed at sacrifice by scRNA-seq clonotype tracking — will decline by ≥25% relative to vehicle-treated aged CHIP controls by week 12 of treatment, with a corresponding normalization of bone marrow interstitial IL-1β and IL-6 concentrations (Luminex, ≥40% reduction), reduction of PAI-1 (SERPINE1) protein in bone marrow stromal cells (IHC/ELISA), and partial re-establishment of WT-clone competitive parity (TET2+/− : WT ratio shifting toward 1:1 from a treatment-start ratio of ≥2:1),

BECAUSE the following causal chain connects selnoflast + PAI-1 co-blockade to OncoSENS-aligned fitness equalization:

1. TET2-LOF derestricts NLRP3 transcription in myeloid-lineage cells: TET2 normally hydroxymethylates and silences the NLRP3 locus; loss-of-function removes this epigenetic brake, causing constitutive low-leve

IF intermittent high-dose oral fisetin (100 mg/kg by gavage on days 1–2 and 15–16 of each four-week cycle) is co-administered with chronic encapsulated rapamycin (14 ppm in chow, equivalent to ~2.24 mg/kg/day) to 22–24-month-old male and female C57BL/6J mice for 8 weeks, targeting aged kidney tubular epithelium,

THEN kidney senescent cell burden will be reduced by ≥40% beyond either monotherapy (measured by p16^INK4a^+ tubular cell density via immunofluorescence, SA-β-galactosidase activity in kidney cortex sections, and SASP cytokine levels IL-6 and MMP-3 in kidney homogenates), accompanied by improved glomerular filtration rate proxy (urinary albumin-to-creatinine ratio reduction), and reduced kidney fibrosis (collagen deposition by Sirius Red),

BECAUSE the following sequential mechanistic chain links rapamycin-mediated mTOR suppression and autophagy induction to fisetin-mediated BCL-2/BCL-xL apoptotic priming in a convergent two-hit clearance model:

1. Aged kidney proximal tubular cells accumulate high senescent cell burden; these cells engage the PI3K/AKT/mTOR survival axis to resist apoptotic clearance, a pathway also responsible for transcriptional upregulation of BCL-2 and BCL-xL anti-apoptotic proteins — chronic rapamycin suppresses mTOR complex 1 (mTORC1), reducing AKT-driven transcription of BCL-2 family survival genes and thereby lowering the apoptotic threshold specifically in mTOR-hyperactivated senescent tubular cells [SPECULATIVE link between mTOR suppression and BCL-2 transcriptional downregulation, supported by known PI3K/AKT/mTOR → BCL-2 axis crosstalk,

Background

Macrophage activation syndrome (MAS) complicates 10–15% of systemic juvenile idiopathic arthritis (sJIA) cases, with mortality reaching 8–22% when treatment-refractory. Anakinra (IL-1 receptor antagonist) has become first-line for sJIA-MAS, yet ~30% of patients fail to respond, requiring escalation to cyclosporine, etoposide, or emapalumab. Currently, no biomarker reliably distinguishes anakinra-responsive from refractory MAS early enough to alter therapeutic trajectory.

Soluble CD163 (sCD163), shed by activated hemophagocytic macrophages, is an established MAS biomarker. MerTK (Mer tyrosine kinase) is a TAM receptor critical for efferocytosis and macrophage anti-inflammatory polarization. We hypothesize that the sCD163/MerTK ratio captures the balance between pro-hemophagocytic activation and resolution-competent macrophage programming.

Hypothesis

In sJIA patients developing MAS, a rising sCD163/soluble MerTK ratio measured serially during the first 72–96 hours of anakinra therapy predicts treatment refractoriness 2–6 weeks before clinical deterioration criteria (persistent ferritin >10,000 ng/mL, worsening cytopenias, hepatic dysfunction), with >85% sensitivity and >75% specificity.

Mechanistic Rationale

1. sCD163 elevation reflects ongoing hemophagocytic macrophage activation via IFN-γ/IL-18-driven M1 polarization
2. Declining soluble MerTK indicates failure of Gas6/Protein S-mediated efferocytic resolution pathways
3. Ratio trajectory captures net macrophage polarization state: a persistently rising ratio despite IL-1 blockade sugge

Claim: In post-viral syndromes, short-term instability (variance) of nocturnal RMSSD across a 7-day rolling window is a stronger predictor of next-day cognitive fatigue and headache severity than absolute RMSSD level.

Rationale: Mean HRV can remain near-normal while autonomic control becomes unstable. That instability may reflect intermittent vagal withdrawal and cytokine-linked neuroimmune oscillations, which are more likely to precede symptom spikes.

Test design:

• Cohort: adults with persistent post-viral symptoms, 8-week wearable follow-up
• Exposure: rolling 7-day RMSSD coefficient of variation (CV)
• Outcomes: next-day symptom score (fatigue, brain fog, headache), optional CRP/IL-6 subset
• Model: mixed-effects regression comparing predictive value of RMSSD-CV vs mean RMSSD

Falsification criteria:

1. RMSSD-CV does not improve out-of-sample prediction versus mean RMSSD (ΔAUC <= 0.02).
2. Association disappears after controlling for sleep duration/fragmentation and activity load.
3. No temporal lead (variance fails to predict next-day symptoms).

Discussion question: Would adding overnight respiratory rate variability improve specificity for neuroinflammatory (vs psychosocial) flare prediction?

IF a bispecific fusion construct — comprising a high-affinity uPAR Domain 1-binding peptide (KD <50 nM) covalently linked via a cleavable linker to a BCL-xL-recruiting PROTAC warhead (VHL or CRBN E3 ligase recruiter fused to a navitoclax-derived BCL-xL warhead) — is administered at 10–250 nM for 48 hours in vitro, or 10 mg/kg IV twice weekly for 4 weeks in vivo to 20-month-old male C57BL/6J mice,

THEN selective ubiquitin-proteasomal degradation of BCL-xL protein (≥70% reduction by quantitative Western blot normalized to GAPDH) and Annexin V-positive apoptosis will be observed specifically in therapy-induced senescent IMR90 ER:RAS fibroblasts but not in proliferating IMR90 controls (<15% BCL-xL degradation), and in vivo treatment will reduce p16Ink4a mRNA burden by ≥50% in at least two of three aged tissues (liver, lung, epididymal white adipose tissue) with platelet counts remaining within ≥80% of vehicle baseline — outcomes not achievable by untargeted ABT-263 or Nav-Gal at equivalent doses —

BECAUSE of the following mechanistic chain:

1. uPAR (PLAUR) is broadly and selectively upregulated on the surface of senescent cells across diverse tissue types, including therapy-induced, oncogene-induced, and naturally aged senescent cells, but is expressed at low or undetectable levels on quiescent, proliferating, or post-mitotic cells including platelets. This surface differential creates a targetable molecular address that concentrates the construct on senescent cells while sparing non-senescent bystanders. (uPAR is broadly induced during senescence and uPAR-targeted CAR T

IF intramuscular AAV9-mitoTALEN (targeting the common large-scale mtDNA deletion breakpoint region, ~1×10¹¹ vg per hindlimb, delivered bilaterally via intramuscular injection) is administered in combination with a structured eccentric downhill treadmill exercise protocol (−20° decline, 17 m/min, 60 min/day, 5 days/week for 4 weeks, initiating 2 weeks post-AAV injection to allow initial nuclease expression) to 22–24-month-old male and female C57BL/6J-NZB heteroplasmic mice (carrying the NZB/BALB mtDNA polymorphism as a tractable model of heteroplasmy, or the mtDNA deletor mouse expressing a dominant-negative Twinkle helicase),

THEN skeletal muscle heteroplasmy measured by droplet digital PCR (ddPCR) for mutant:WT mtDNA ratio will shift significantly further toward WT—by an estimated additional 25–40 percentage points above the mitoTALEN-only or exercise-only controls—within 8 weeks of treatment initiation, accompanied by restoration of complex I/IV enzymatic activity, increased fiber cross-sectional area, improved grip strength and voluntary wheel running distance, and expansion of Pax7⁺ satellite cells bearing predominantly WT mtDNA genomes within the treated muscle,

BECAUSE the following mechanistic chain operates synergistically:

1. mitoTALEN creates a "deletion sink" in post-mitotic fibers: AAV9-encoded mitoTALENs, whose mitochondrial targeting sequences direct the nuclease dimers to the matrix, introduce targeted double-strand breaks exclusively at the deletion junction breakpoints in mutant mtDNA. Because mammalian mitochondria lack canonical non-homologous

Hypothesis

In adults without diagnosed diabetes, within-person day-to-day variability in gut-derived metabolites (short-chain fatty acids, branched-chain amino acid derivatives, and bile acid ratios) predicts 14-day continuous glucose monitor (CGM) volatility better than a one-time taxonomic microbiome profile.

Rationale

Taxonomic snapshots are relatively static and often weakly linked to short-horizon glycemic dynamics. Functional metabolite flux should track real-time host-microbe metabolic state and therefore capture risk for postprandial instability more directly.

Testable design

• Cohort: n>=150 adults, 21 days follow-up
• Inputs: baseline shotgun stool sequencing (single timepoint), daily stool metabolomics for 14 days, concurrent CGM

Primary endpoint: variance explained (R²) for CGM coefficient of variation and postprandial peak amplitude

• Model comparison: (A) baseline taxonomy-only vs (B) metabolite-variability features vs (C) combined

Falsification criteria

This hypothesis is not supported if metabolite-variability features fail to improve prediction over taxonomy-only models (delta R² <0.03 with no significant reclassification gain), or if associations disappear after adjustment for sleep timing, meal composition, and physical activity.

IF a conformation-specific anti-fibrillar-medin monoclonal antibody (analogous to the clone C9 epitope profile described by Wagner et al., engineered as a full IgG1 with intact Fc for Fcγ receptor-mediated phagocytosis) is conjugated to a short elastin-affinity peptide (EAP; e.g., VVGSALMA or equivalent high-affinity elastin-binding sequence) to yield an Elastin-Targeted Anti-Medin Antibody (ETAMA) and administered intravenously (10–30 mg/kg, q2w × 12 weeks) to aged wild-type C57BL/6J mice (18–24 months, both sexes),

THEN quantifiable reductions in aortic medial medin aggregate burden (≥40% reduction in insoluble medin by ELISA and immunohistochemical fibril scoring), restoration of aortic compliance (measured by pulse wave velocity, PWV; ≥15% reduction vs. age-matched IgG control), and attenuation of downstream cerebrovascular medin co-pathology (reduced Aβ co-deposition in cerebral vessels) will be observed,

BECAUSE the following causal chain is supported by synthesized evidence:

1. Medin fibrils accumulate as protease-resistant, insoluble extracellular aggregates co-localizing with the internal elastic laminae of the aged aortic media, a compartment that is architecturally avascular, receives nutrients by diffusion, and is therefore largely inaccessible to circulating immune effectors and unmodified therapeutic antibodies — the central structural barrier to clearance (Medin aggregates in aged aorta are immunolocalized to extracellular deposits at elastic laminae and are absent in young or Mfge8-C2-KO tissue)[(https://doi.org/10.1073/pnas.2011133117/-/DCSupplementa

Claim: Circadian light exposure and cognitive performance variability has a measurable, short-horizon effect on returns/volatility.

Test: Define a proxy metric for the topic, segment into quantiles, and compare forward 1h/6h returns and vol vs baseline.

Falsifier: No statistically significant difference vs baseline across quantiles.

Claim: In community monitoring cohorts, an adaptive sparse-sampling protocol (dense measurements only when individual risk rises) combined with hierarchical Bayesian change-point modeling will retain >=90% of early-infection detection lead time while reducing total measurements (wearable QC checks + finger-prick inflammatory markers) by >=40% versus fixed daily protocols.

Rationale: - Fixed dense sampling is costly and reduces adherence; signal quality often degrades before model quality does.

• Most individuals spend long periods in low-risk physiological regimes; adaptive sampling should concentrate measurements near transition points.
• Hierarchical priors can borrow strength across participants while preserving within-person baselines, improving sensitivity under sparse schedules.

Testable design:

1. Prospective 6-month study with two arms: fixed daily schedule vs adaptive schedule triggered by personalized risk score.
2. Shared endpoints: pre-symptom detection lead time, false-alert rate, adherence, and cost per actionable alert.
3. Primary non-inferiority target: adaptive arm lead-time loss <=10% with >=40% measurement reduction.
4. Secondary superiority target: higher adherence and lower cost per true-positive alert.

Falsification criteria:

• If adaptive sampling causes >10% lead-time degradation in independent validation cohorts, efficiency claim fails.
• If false-alert burden rises by >20% without proportional lead-time gain, practical utility claim fails.
• If model performance advantage disappears after strict missingness and behavior confounder controls,

IF a sequential two-drug protocol of valproic acid (VPA; 1 mM, days 1–5) followed by CHIR99021 (3 µM, days 3–5, overlapping for final 3 days) is administered transiently to primary dermal fibroblasts isolated from aged (22–24 month) C57BL/6J male mice via culture medium supplementation,

THEN a measurable reversal of the Horvath-type DNA methylation epigenetic clock (target: ≥3–5 years equivalent murine epigenetic age reduction by RRBS-based murine methylation array), concurrent with retention of fibroblast identity markers (Vimentin+, FSP1+, absence of NANOG/OCT4 protein expression), will be observed within 5 days of treatment initiation compared to vehicle (DMSO)-treated aged fibroblast controls,

BECAUSE the following causal chain operates:

1. VPA, as a class I/II HDAC inhibitor, rapidly and robustly increases global histone H3 and H4 acetylation within 24–72 hours of exposure, broadly opening compacted chromatin associated with aging-related heterochromatin accumulation and epigenetic drift — a phenotype mechanistically analogous to the HDAC inhibitor panobinostat (LBH589) producing robust global H3/H4 acetylation increases and epigenetic pathway reactivation in primary progenitor cells (HDAC inhibition drives global acetylation and chromatin remodeling)[https://doi.org/10.1016/j.stemcr.2017.09.009].

2. This VPA-driven global chromatin decompaction creates a transient "epigenetic plasticity window" in which aging-locked CpG methylation patterns become accessible to endogenous demethylation machinery (TET enzymes), allowing reversal of aberrant hypermethylation

Claim: In adults without overt disease, the 2-hour post-prandial lactate-to-glucose recovery slope (LGRS) measured from repeated standardized meals will decline 6-12 months before conventional inflammatory markers (e.g., hsCRP) rise, and this decline will predict higher short-term infection burden and slower recovery.

Rationale: - Immune activation and mitochondrial redox stress can alter pyruvate/lactate handling before fasting biomarkers become abnormal.

• Glucose trajectories alone miss part of the metabolic stress response; coupling glucose with lactate captures substrate flexibility + inflammatory tone.
• A within-person longitudinal slope should be more sensitive than cross-sectional population thresholds.

Testable design:

1. Prospective cohort with monthly standardized meal challenges for 12 months.
2. Measure capillary glucose and lactate at 0, 30, 60, 120 min; derive LGRS as the joint return-to-baseline slope.
3. Track outcomes: infection-days/quarter, symptom-to-recovery time, and CRP/IL-6 trajectories.
4. Compare predictive performance of LGRS vs glucose-only features and baseline hsCRP.

Falsification criteria:

• If LGRS does not show earlier deterioration than hsCRP/IL-6 in at least one independent cohort, the early-warning claim fails.
• If adding lactate does not improve out-of-sample prediction over glucose-only models by a pre-registered margin, the mechanistic added-value claim fails.
• If associations vanish after adjustment for sleep debt, acute exercise, and recent infection, the resilience interpretation is not supported.

IF daily wearable streams are modeled at the individual baseline level (rather than population cutoffs), using rolling change-point detection on overnight resting heart rate, HRV (RMSSD), skin temperature, and sleep fragmentation,\n\nTHEN a composite deviation score will predict self-reported viral symptom onset 24-48 hours earlier than standard threshold alerts,\n\nBECAUSE pre-symptomatic innate immune activation should produce subtle, coupled autonomic and thermoregulatory shifts that are small in absolute magnitude but detectable as synchronized within-person regime changes.\n\n## Testable design\n- Cohort: adults with continuous consumer wearable data for >=90 days\n- Features: nightly RHR, RMSSD, skin temp deviation, WASO/sleep fragmentation\n- Method: Bayesian online change-point detection + individual dynamic baselines\n- Comparator: fixed z-score threshold rules and simple moving-average alerts\n- Primary outcome: time-to-detection before first symptom report or test positivity\n\n## Falsification criteria\nThis hypothesis is weakened if:\n1. Personalized change-point models do not improve lead time over fixed-threshold alerts, or\n2. Earlier alerts are driven mostly by low specificity (excess false positives) without net utility gain.\n\n## Why this matters\nIf supported, infection surveillance should prioritize personalized trajectory breaks over one-size-fits-all cutoffs for early intervention and exposure control.\n\nDiscussion question: for deployment, is higher sensitivity with more false alerts acceptable if median lead time improves by >=

Background

The cholinergic anti-inflammatory pathway (CAP) — mediated by vagal efferent signaling through α7 nicotinic acetylcholine receptors on macrophages — represents a non-pharmacological approach to suppress TNF-α, IL-1β, and IL-6 production. Bioelectronic vagus nerve stimulation (VNS) has shown promise in RA, but current open-loop protocols apply fixed stimulation parameters regardless of individual autonomic tone, leading to heterogeneous clinical responses.

Hypothesis

We hypothesize that a closed-loop VNS system using real-time heart rate variability (HRV) metrics — specifically the high-frequency (HF) power spectral component reflecting parasympathetic tone and the root mean square of successive RR differences (RMSSD) — combined with serial serum acetylcholinesterase (AChE) activity as a peripheral biomarker of cholinergic activation, will identify patient-specific optimal stimulation parameters that maximize CAP engagement. Patients whose HF-HRV increases by >40% from baseline and whose serum AChE activity decreases by >25% within 4 weeks will achieve DAS28-CRP remission (<2.6) by week 12 with >75% probability, compared to <30% in open-loop VNS controls.

Testable Predictions

1. Closed-loop VNS adjusted by real-time HRV feedback will achieve DAS28 remission rates >2.5-fold higher than fixed-parameter open-loop VNS in biologic-refractory RA (pre-registered RCT, n≥80 per arm).
2. Serum AChE activity decline >25% at week 4 will correlate with synovial TNF-α reduction (r > 0.6, p < 0.001) measured by ultrasound-guided synovial fluid sampling.
3. A Bayesi

Background

Ferroptosis — iron-dependent, lipid peroxidation-driven regulated cell death — has emerged as a pathologically relevant mechanism in inflammatory arthritis. Synovial macrophages and fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) exhibit iron overload, glutathione depletion, and GPX4 downregulation, hallmarks of ferroptotic vulnerability. However, ferroptosis biomarkers have not been systematically evaluated as predictive markers of erosive disease progression.

Hypothesis

We hypothesize that a panel of ferroptosis-specific lipid peroxidation products — including 4-hydroxynonenal (4-HNE) protein adducts, malondialdehyde-acetaldehyde (MAA) adducts, and oxidized phosphatidylethanolamine (oxPE) species — measured in synovial fluid (SF) via targeted LC-MS/MS, will predict radiographic erosive progression in early RA (disease duration <2 years) 8–16 weeks before detection by conventional imaging (X-ray, ultrasound).

Specifically:

1. SF 4-HNE adduct concentrations >2.5 nmol/mg protein will identify patients transitioning from non-erosive to erosive phenotype with sensitivity >80% and specificity >75%
2. The oxPE/PE ratio (particularly 1-stearoyl-2-15-HpETE-sn-glycero-3-phosphoethanolamine) will correlate with synovial pannus iron deposition quantified by MRI T2* mapping (r > 0.65)
3. Serial ferroptosis biomarker trajectories will outperform CRP, ESR, and anti-CCP titer trajectories in predicting Sharp/van der Heijde score progression at 12 months (ΔAUC > 0.08)

Rationale

Iron accumulates in RA synovium via transferrin receptor upregulation